We evaluated CNA35 as a collagen marker in healthy and atherosclerotic arteries of mice after both ex vivo and in vivo administration and as a molecular imaging agent for the detection of atherosclerosis. CNA35 conjugated with fluorescent Oregon Green 488 (CNA35/OG488) was administered ex vivo to mounted viable muscular (uterine), elastic (carotid), and atherosclerotic (carotid) arteries and fresh arterial rings. Two-photon microscopy was used for imaging. CNA35/OG488 labeling in healthy elastic arteries was compared with collagen type I, III, and IV antibody labeling in histologic sections. For in vivo labeling experiments, CNA35/OG488 was injected intravenously in C57BL6/J and apolipoprotein E 2/2 mice. Ex vivo CNA35/OG488 strongly labeled collagen in the tunica adventitia, media, and intima of muscular arteries. In healthy elastic arteries, tunica adventitia was strongly labeled, but labeling in tunica media and intima was prevented by endothelium and elastic laminae. Histology confirmed the affinity of CNA35 for type I, III, and IV collagen in arteries. Strong CNA35/OG488 labeling was found in atherosclerotic plaques. In vivo applied CNA35/OG488 minimally labeled the tunica intima of healthy carotid arteries. Atherosclerotic plaques in apolipoprotein E 2/2 mice exhibited large uptake. CNA35/OG488 imaging in organs revealed endothelium as a limiting barrier for in vivo uptake. CNA35/OG488 is a good molecular imaging agent for atherosclerosis.
C OLLAGEN is a major constituent of the extracellular matrix in vasculature and is important for maintaining vascular integrity and stability. [1] [2] [3] In advanced atherosclerosis, collagen content is considered a major determinant for plaque stability. [2] [3] [4] [5] Furthermore, collagen is one of the structural determinants for arterial stiffness, 1, 6, 7 which is associated with aging, 6, 7 hypertension, 8 and diabetes. 9 Insight into vascular collagen structure, distribution, function, and content may lead to a better understanding of the pathogenesis of these vascular diseases. Therefore, a method to visualize collagen architecture in viable intact arteries is essential.
Imaging of vascular collagen in viable arteries excludes (immuno)histochemistry because this requires fixation or freeze-thawing to obtain arterial sections. Moreover, routinely used histologic collagen stains such as Picrosirius Red or antibodies against specific types of collagen have limited applicability for viable samples owing to the staining procedures required or limited depth penetration into thick tissues. Thus, a fluorescent marker that specifically labels collagen in viable arteries and a microscopy method that combines large penetration depth with optical sectioning are required. This combination will allow detailed imaging of structures deep in arterial tissue and three-dimensional reconstructions.
Two-photon laser scanning microscopy (TPLSM) is established as an imaging modality that allows structural and functional imaging of viable intact arteries at the cellular level with good penetration depth and optical sectioning. [10] [11] [12] [13] [14] Arterial wall collagen can be directly visualized using its second harmonic generation (SHG) resulting from the TPLSM pulsed laser excitation. 10, 12, [15] [16] [17] However, in contrast to small arteries, 17 detection of SHG signal originating from collagen in the tunica media and intima in viable large arteries of mice is rather difficult. 10 Recently, Krahn and colleagues developed a collagenspecific fluorescent probe based on CNA35. 18 CNA is a collagen binding adhesion protein found in Staphylococcus aureus and involved in wound infection caused by these pathogenic bacteria. 19, 20 The collagen binding part of this transmembrane protein is called CNA35 and consists of the first two soluble domains, N1 and N2. Multiple binding sites have been observed for binding of CNA35 to both type I and type II collagen. 19, 21 Apparent K d s (dissociation constant) ranging from 20 nM to 30 mM have been reported, depending on the specific type of collagen. [18] [19] [20] [21] [22] Based on the recently determined x-ray structure of CNA35 in the presence of a short collagen triple helix, the so-called ''collagen hug model'' has been proposed. 22 According to this model, binding of collagen is initiated by a low-affinity interaction between the collagen triple helix and a complementary trench located on the N2 domain. The N1 domain is not yet involved at this stage. The next step is reorientation and stabilization of the N1 domain, as a result of which, CNA35 is wrapped around the bound collagen. Finally, a C-terminal extension of the N2 domain stretches toward the N1 domain, forming a b strand that complements one of the b sheets of the N1 domain.
As a collagen marker, CNA35 has several potential advantages over existing collagen markers 18 : (1) CNA35 can be applied to both viable and freeze-thawed tissues; (2) antibodies are more expensive, which excludes in vivo experiments that require large amounts of antibody; (3) collagen antibodies are mostly specific for one type of collagen, and although this may be advantageous for histology, it is a serious drawback for the detection of overall collagen content; (4) CNA35 is known to bind reversibly to its target, which is important for a vital staining to avoid functional effects; (5) CNA35 conjugated with Oregon Green 488 (CNA35/OG488) yields a much stronger signal than SHG, allowing visualization of much smaller, newly formed fibrils; (6) CNA35 is approximately five times smaller than antibodies against collagen, which could be beneficial for penetration into thick viable samples; and (7) CNA35 can easily be conjugated with contrast agents, making it suitable for a range of imaging techniques.
The feasibility of collagen labeling with CNA35 conjugated with fluorescent Oregon Green 488 (CNA35/ OG488) has already been shown in cell cultures and native tissues by Krahn and colleagues. 18 Furthermore, they verified that CNA35 has a high affinity for type I, III, and IV collagen but not for other types of collagen or other extracellular matrix proteins, such as elastin, fibrin, and laminin. Collagen types I, III, and IV are the most abundant collagens in the vessel wall, 23 which are also associated with atherosclerosis and plaque progression. 2, 5 Type I and III collagen are fibrillar collagens 2 mainly located in the tunica adventitia and media. 23 Type IV collagen, a basement membrane-associated type of collagen, 2 is mainly located in the tunica media, surrounding the vascular smooth muscle cells (vSMCs), and in the tunica intima, where it forms the general scaffold of the basement membrane. 2 The goal of this study was to determine the ex vivo and in vivo applicability of CNA35/OG488 for imaging of collagen in viable mounted arteries using TPLSM. To this purpose, we applied CNA35/OG488 ex vivo to fresh transversal arterial rings and mounted healthy muscular (uterine), elastic (carotid), and atherosclerotic (carotid) arteries. Finally, CNA35/OG488 was administered in vivo to investigate CNA35/OG488 uptake in healthy and atherosclerotic arteries (and organs) and to determine its feasibility as a molecular imaging agent for the detection of atherosclerosis.
Methods

Animals
All experiments were permitted by the local ethics committee on the use of laboratory animals. Procedures were in accordance with institutional guidelines. For ex vivo experiments, euthanasia was performed by a mixture of CO 2 and O 2, after which, arteries were isolated. Carotid artery segments (common part and bifurcation) were excised from 20-to 22-week-old C57BL6/J (n 5 6) and apolipoprotein E 2/2 (ApoE 2/2 ) (n 5 6) mice (Charles River, Maastricht, the Netherlands). C57BL6/J mice were fed a chow diet; ApoE 2/2 mice were fed a Western diet for 14 weeks (Western Diet 4021.06, Hope Farms, Woerden, the Netherlands). Uterine (midsection, n 5 3) arteries were obtained from 12-to 16-week-old nonpregnant female C57BL6/J mice (Charles River) on a chow diet.
For in vivo labeling experiments, two C57BL6/J (fed a chow diet) and five ApoE 2/2 (fed a Western diet) mice (20-22 weeks) were anesthetized by subcutaneous administration of a mixture of xylazine (Xylazin, Ceva Sante Animale BV, Naaldwijk, the Netherlands; 15 mg/kg body weight) and ketamine (Nimatek, Eurovet, Cuijk, the Netherlands; 75 mg/kg body weight). After CNA35/OG488 infusion, the animals were euthanized (overdose of ketamine-xylazine), blood was withdrawn, and carotid arteries, kidneys, liver, spleen, lungs, and the heart were isolated.
Preparation and Staining Procedures
CNA35/OG488 Administration Ex Vivo
Fresh Transversal Arterial Rings. To test whether CNA35/ OG488 has affinity for collagens in all tunicae of arteries, 1 mm-thick rings were cut off from isolated common carotid arteries (n 5 3). These rings were incubated for 60 minutes with 1.5 mM CNA35/OG488 in Hanks' Balanced Salt Solution (HBSS, Gibco BRL 15510-027; Invitrogen, Breda, the Netherlands; pH 7.4) containing NaCl 144 mM, HEPES 14.9 mM, glucose 5.5 mM, KCl 4.7 mM, CaCl 2 2.5 mM, KH 2 PO 4 1.2 m M, and MgSO 4 1.2 mM. Nuclei in one arterial ring were labeled with the deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) marker SYTO 41 (l max emission 5 480 nm, final concentration 1.5 mM; Molecular Probes, Leiden, the Netherlands). After incubation, the rings were embedded in 1.5% agarose gel dissolved in HBSS for stabilization during imaging. 12 In these rings, elastic bands were visualized using the autofluorescence properties of elastin. 17 Whole-Mount Arteries. To explore the characteristics of CNA35/OG488 in structurally intact and viable arteries, muscular (uterine) and elastic (carotid) arteries were mounted in a perfusion chamber, as described previously. 10, 24 Briefly, isolated arteries were mounted on two glass micropipettes in a perfusion chamber (volume 10 mL; IDEE BV, Maastricht, the Netherlands). The whole system was filled with HBSS. Correction for vascular shortening owing to isolation was performed at a transmural pressure of 100 mm Hg by stretching the vessel until its bends were removed. Subsequently, vessels were imaged at a transmural pressure of 80 mm Hg to mimic physiologic conditions. Viability was maintained for up to 4 hours. 10 All ex vivo experiments were performed at room temperature. In case of carotid artery bifurcations, the mounting procedure was to a large extent similar to the one used for common carotid arteries, except that the internal branch was mounted on a glass micropipette in the perfusion chamber, whereas the external branch and other side branches of the bifurcation were ligated, after which, intraluminal pressure was applied (40-80 mm Hg, depending on the maximum pressure the ligations of the side branches could withstand) and length was corrected. TPLSM imaging was restricted to the central portion of the mounted vessel segment, which included the bifurcation.
For specific labeling of vascular structures and cells and to verify arterial viability, several fluorescent markers were applied: CNA35 conjugated with Oregon Green 488 (OG 488, l max emission 5 510 nm) was used as a collagen marker (final concentration 1.5 mM; kindly provided by Technische Universiteit Eindhoven, Eindhoven, the Netherlands). 18 CNA35/OG488 contains approximately three OG488 labels per CNA35 protein. 18 Final CNA35/ OG488 concentration was optimized by testing a range of concentrations from 1.0 to 5.0 mM in elastic arteries. Nuclei of cells with an intact cell membrane were labeled with the viable cell membrane permeable DNA/RNA marker SYTO 41 (final concentration 2.5 mM). Propidium iodide (PI; l max emission 5 620 nm, final concentration 1.5 mM; Molecular Probes) was used to assess cell membrane integrity and, hence, cell viability in mounted arteries. Elastin was labeled with eosin (l max emission 5 545 nm, final concentration 0.5 mM; Molecular Probes). 12 All labels were applied both intraand extraluminally. Fluorescent probes were diluted in HBSS and added 30 minutes prior to the start of image acquisition. To avoid additional manipulations of the artery, fluorescent probes remained present during image acquisition. The presence of the probes did not alter their labeling characteristics or the viability of the arteries or reduce the image quality.
Vascular Damage. To further investigate CNA35/OG488 penetration in the arterial wall, mounted elastic arteries were mechanically damaged (n 5 2) by pinching the artery (two pinches, 3 seconds per pinch) at one position using a fine forceps (FST #5, biology tip, FST, Vancouver, BC). CNA35/OG488 was applied intraluminally in both arteries; labels remained present during and after pinching. Nuclei of cells with an intact cell membrane were labeled with the DNA/RNA marker SYTO 41 (final concentration 2.5 mM); the nuclei of cells with lost membrane integrity were labeled with PI. One artery was additionally labeled with eosin for visualization of elastin. Images were recorded both immediately and 30 minutes after pinching.
Histology
At the end of the ex vivo experiments, arteries were fixed luminally and abluminally with formalin (10% in HBSS) at a transmural pressure of 80 mm Hg for 24 hours.
Following fixation, arteries were embedded in paraffin, 25 after which, 5 mm-thick longitudinal and transversal sections were cut. Before the start of histologic staining procedures, sections were deparaffinized in xylene and rehydrated in ethanol. Endogenous peroxidase activity was blocked by incubation with methanol plus 3% hydrogen peroxide for 15 minutes. Sections were washed with Trisbuffered saline (TBS) containing NaCl 136.9 mmol/L, Trizma base 5.0 mmol/L, 1% bovine serum albumin, and 0.1% Tween 20, pH 7.6 and treated with 0.1% pepsin in 0.01 M HCl for 30 minutes. After washing, sections were incubated with CNA35/OG488 (1 mM), primary rabbit antihuman polyclonal antibodies against collagen type I or III (both 1:10; Biogenesis, Kingston, NH), or antihuman monoclonal antibody against collagen type IV (1:400 25 ) for 60 minutes at room temperature. Antibodies and CNA35/ OG488 were dissolved in TBS. The human antibodies were shown to stain mouse collagens as well with similar specificity (unpublished data). After washing with TBS, CNA35/OG488-treated sections were coverslipped using Entellan (Merck, Darmstadt, Germany). Sections treated with a primary antibody were washed, after which, secondary biotin-labeled swine antirabbit antibody was applied (1:1,000; DAKO, Glostrup, Denmark). Subsequently after washing, sections were incubated with streptavidin-avidin biotin complex-horse radish-peroxidase (streptavidin-ABC-HRP) (1:500; DAKO) for 30 minutes at room temperature. Diaminobenzidine (DAKO) treatment (10 minutes at room temperature) was used for chromogenic development. Sections were coverslipped using Entellan.
CNA35/OG488 Administration In Vivo
CNA35/OG488 was diluted in a standard physiologic salt infusion fluid (Braun AG, Melsungen, Germany) to a final concentration of 19 or 38 mM. Depending on the desired concentration, one or two boluses of 200 mL each were infused via the tail vein of the anesthetized mice. Several administration doses were tested: 200 mL at 19 mM (n 5 2; one C57BL6/J, one ApoE 2/2 ); 200 mL at 38 mM (n 5 1; ApoE 2/2 ); and 2 3 200 mL at 38 mM (n 5 4; one C57BL6/J, three ApoE 2/2 ). In the latter, CNA35/OG488 was infused in two boluses of 200 mL each (instead of one bolus of 400 mL) to enhance the total circulation time of the probe. Moreover, a volume of 400 mL is too high a volume load for a single infusion in mice. Since 38 mM was the maximal concentration of the available stock solution, a further increase in the concentration required an increase in the total infusion volume above 400 mL and was therefore not used. The incubation time per infusion was 45 minutes; the total incubation time was 90 minutes. To exclude the labeling effects of CNA35/OG488 after euthanasia, contact of the two carotid arteries with spoiled blood was avoided. Both carotid arteries were mounted as described above. After mounting, anti-CD31 conjugated with phycoerythrin (PE) was diluted in HBSS and applied intraluminally as a marker for endothelial cells (l max emission 5 570 nm, final concentration 8 mg/mL; BD Biosciences, Alphen aan den Rijn, the Netherlands). CNA35 content in the blood was studied in blood smears. Kidneys, liver, spleen, lungs, and heart were washed in HBSS and embedded in agarose gel (1.5% dissolved in HBSS).
Imaging
The microscope setup used for imaging of viable arteries (and organs) has been described previously. 10, 12 In short, a Bio-Rad 2100MP TPLSM was used (Bio-Rad, Hemel Hempstead, UK), coupled to a Nikon E600FN microscope (Nikon Corporation, Tokyo, Japan). The excitation source was a pulsed (140 fs) Ti:sapphire laser (Spectra Physics Tsunami, Mountain View, CA) tuned and mode-locked at 800 nm. Laser light reached the sample through a 603, numerical aperture (NA) 1.0 water dipping objective (working distance 2 mm, maximum field of view 206 3 206 mm). When required, resolution was enhanced by optical zoom (consequently, the field of view was reduced). To avoid thermal and photochemical damage to the sample, the intensity of the excitation laser was kept as low as possible. 26 For simultaneous imaging of up to three different fluorescent markers, filters were used to split the emitted fluorescence light into three different wavelength ranges. Each wavelength range corresponded to (part) of the emission spectrum of the fluorophores used and was collected by one of three photomultiplier tubes (PMTs): SHG 400 to 420 nm (PMT I); SYTO 41, 460 to 480 nm (PMT I); CNA35/OG488, 520 to 550 nm (PMT II); eosin, 530 to 560 nm (PMT III); PI, 570 to 610 nm (PMT III); CD31/PE, 570 to 610 nm (PMT III). For simultaneous imaging of a combination of fluorescent markers, each PMT was tuned for minimal bleedthrough of fluorescent signal of the used markers.
From each PMT, separate images of 512 3 512 pixels were obtained, saved, and combined into an red, green, and blue (RGB) image. The frame rate was 0.1 Hz with a pixel dwell time of 39 ms, or 0.3 Hz with a pixel dwell time of 0.12 ms combined with Kalman filtering for noise reduction (n 5 3 cycles). Optical sections were collected in the x-y direction; series of x-y sections at successive depth positions (z-stack) were collected for reconstruction of three-dimensional images. 10 Incorrect alignment of the micropipettes in the perfusion chamber occasionally caused imaging of the arteries in a slightly oblique plane. Atherosclerotic plaque detection in the mounted vessel segments was performed by the use of bright-field microscopy where plaques show up as dark and less translucent regions on a bright background (of healthy vessel segments). This initial detection was further supported by the three-dimensional capability of TPLSM, which allows plaques to be identified as a deviation from the staining pattern as visible in the vessel wall of healthy carotid arteries.
Histologic sections were imaged using a Leica DM 5000B microscope (Leica Microsystems GmbH, Wetzlar, Germany) coupled to a Leica DC 300FX digital camera. A 1003 oil objective (NA 5 1.4) was used.
Images of histologic sections were analyzed using Qwin morphometry software (Leica, Cambridge, UK). Image analysis of TPLSM data was performed with the Image-Pro Plus 6.0 software (Media Cybernetics, Silver Spring, MD). Three-dimensional reconstructions were performed using the 3D-constructor 5.1 package for Image-Pro Plus (Media Cybernetics).
Results
Histology
To verify the location of the three main types of collagen in large arteries of mice, histologic sections of elastic arteries were prepared and labeled with collagen type I, III, or IV antibodies. As an example, a histologic section specifically stained for type IV collagen is shown in Figure 1A . Type IV collagen (brown stain) is clearly present in the tunica media between the external elastic lamina (EEL) and intermediate elastic lamina and surrounding the vSMCs (red arrow). A thin sheet of type IV collagen (green arrow) is present at the luminal site of the tunica intima, which corresponds to the endothelial basement membrane. No type IV collagen is visible in the tunica adventitia. The distribution of type I, III, and IV collagen as detected in these histologic sections is illustrated schematically in Figure 1B . Type I and III collagen was exclusively observed in the tunicae adventitia and media, whereas type IV collagen was present in the tunicae media and intima but not in the tunica adventitia. Application of CNA35/OG488 on histologic sections of elastic arteries revealed that CNA35 labeled collagen in all tunicae ( Figure 1C ) and demonstrated its potential as a collagen label in fixed arteries. The elastic laminae (blue) were not labeled by CNA35/OG488. Ex Vivo CNA35/OG488 Labeling in Healthy Arteries: Where Does CNA35/OG488 Go To?
Mounted Muscular and Elastic Arteries
To establish the labeling characteristics of CNA35/OG488 in viable and structurally intact arteries, we show three x-y sections of a z-stack at comparable positions in the arterial wall of mounted, viable muscular (uterine; Figure 2 , A, C, and E), and elastic (carotid; Figure 2 , B, D, and F) arteries. Three-dimensional reconstructions of both z-stacks are shown in Figure 2 , G to H. Arteries were labeled for collagen (green, CNA35/OG488), elastin (red, eosin), and nuclei (blue, SYTO 41). Note that in both arterial types, the elastin structures do not exhibit any CNA35/OG488 labeling. The tunica adventitia is a layer that contains large amounts of type I and III collagen (see Figure 1B ). 23 Figure  2 , A and B, displays collagen (green), several thin elastin fibers (red), and fibroblast-like cell nuclei (red arrow). In both muscular and elastic arteries (see Figure 2 , A-B), collagen is clearly visible in the tunica adventitia, but in elastic arteries (see Figure 2B ), the adventitial collagen layer is thicker and the density of collagen fibers is higher, as already shown by SHG. 10 Also, in the tunica media (see Figure 2 , C and D), collagen labeling of elastic and muscular arteries differed significantly. In the muscular artery (see Figure 2C ), collagen fibers are clearly distinguishable between the ''cigar-shaped'' vSMC nuclei (green arrow), whereas in the elastic artery, collagen labeling is completely absent in the tunica media (see Figure 2D ). Elastin (red) in the muscular arteries has a mesh-like structure in the EEL, and between the single layer of vSMCs (green arrow), long elastic fibers are visible. In the tunica media of the elastic artery (see Figure 2D ), collagen labeling is completely absent. The structure of elastin (red) is more compact and completely surrounds the two layers of vSMCs (green arrow). Finally, in the tunica intima of muscular arteries (see Figure 2E ), CNA35 labeling visualizes a (barely visible) hazy layer of collagen on the luminal side of the uniformly shaped internal elastic layer (IEL), with a few small sites with increased intensity (pink arrow). These sites are located in and around fenestrae present in the IEL. Furthermore, endothelial cell nuclei (white arrow) and part of the lumen are noticable. In the A and B show the tunica adventitia of a muscular and an elastic artery, respectively. Note the differences in collagen structure and content in the tunica adventitia of both arteries. In the tunica media of a muscular artery (C), collagen fibers (green) are clearly distinguishable between the vascular smooth muscle cells (vSMCs, green arrow). Elastin has a mesh-like structure. The tunica media of an elastic artery (D) contains no CNA35/OG488-labeled collagen. The structure of elastin (red) is more compact and completely surrounds vSMC nuclei (green arrow). E represents the tunica intima of a muscular artery with the internal elastic layer (IEL) (red), endothelial cell nuclei (white arrow), and part of the lumen. A strong collagen signal (pink arrow) is visualized near several fenestrae in the IEL. Furthermore, a hazy layer of collagen is present on the luminal site of the IEL. The tunica intima of an elastic artery (F) contains endothelial cells (white arrow) and a less fenestrated IEL (red) and lacks the hazy layer of collagen at the luminal site of the IEL. Only a few CNA35/OG488-labeled sites (white dotted lines) are present between the endothelial cells and the IEL. G and H show threedimensional reconstructions of both z-stacks of the muscular and the elastic artery, respectively. Note the difference in arterial wall thickness between both arterial types. tunica intima of an elastic artery (see Figure 2F ), endothelial cells are clearly observable. The IEL (red) is also uniformly shaped but contains fewer fenestrations. No hazy layer of collagen is observable. Furthermore, only a few CNA35/OG488-labeled sites (encircled by white dotted lines) are visible between the vascular endothelial cells and the IEL. Figure 3 shows that CNA35/OG488-labeled sites in the tunica intima of elastic arteries are mainly, but not exclusively, found in close proximity to (damaged) PIpositive endothelial cells (pink arrow). Also, areas behind SYTO 41-positive endothelial cells (green arrow) sometimes contain CNA35/OG488 (white arrow). PI staining is indicative of a loss of cell integrity and occasionally occurs as a consequence of the preparation and mounting procedure. 10 However, in the present setup, the number of PI-positive cells in mounted and stained arteries remained low and stable for up to 4 hours after CNA35/ OG488 incubation.
Final CNA35/OG488 concentration, ranging from 1.0 to 5.0 mM, did not influence labeling intensity and pattern in the tunica media and intima of either vessel type. By contrast, mechanically induced damage (pinching with a forceps) of elastic arteries resulted in a large increase in collagen labeling in the tunica intima. A bright collagen layer became visible at the damaged site, whereas in the undamaged area, such a collagen layer cannot be distinguished ( Figure 4A ). Furthermore, vSMCs (red arrow) and endothelial cells (white arrow) are detectable only in the undamaged area; the tunica media remained unlabeled by CNA35/OG488 in the damaged area (see Figure 4A ). Pinching with a forceps did not damage the elastin layers of the artery, as is illustrated in Figure 4B . The IEL (homogeneous orange layer) in the damaged and undamaged area is comparable, whereas the vSMCs (red arrow) are again observable only in the undamaged part of the artery (as in Figure 4A ). Adventitial collagen was unaltered at damaged sites (not shown).
CNA35/OG488 Labeling in Fresh Arterial Rings
Given that in viable mounted elastic arteries, CNA35/ OG488 did not label collagen in the tunica media, we tested whether the internal and external elastic laminae limit the penetration of CNA35/OG488 into the tunica media of fresh arteries. To that end, we labeled fresh rings of elastic arteries with CNA35/OG488. Indeed, CNA35/ OG488 appeared to label collagen in the tunica media of these arterial rings. As shown in Figure 5 , CNA35/OG488 was observed adjacent to the elastic laminae (see Figure  5A ) and between vSMCs (red arrow) in the tunica media ( Figure 5B ), which is in agreement with data from our histochemical experiments (see Figure 1B ) and from the literature. 23 As in mounted arteries, the tunica adventitia of fresh arterial rings also showed large uptake of CNA35/ OG488 (see Figure 5A ). The tunica intima (see Figure 5A ) exhibited collagen labeling at the luminal site of the IEL, the location of the basement membrane that contains type IV collagen. 2 The three elastic laminae were not labeled with CNA35/OG488 but were visible in blue owing to autofluorescence (see Figure 5A ). Furthermore, vascular smooth muscle cells (''cigar-shaped'' cell nuclei) located in the tunica media and endothelial cells (green arrow) in the tunica intima can be clearly identified. CNA35/OG488 uptake in the tunica intima is increased in areas near PI-positive endothelial cells (pink arrow). However, not all CNA35/OG488-labeled areas in the tunica intima are in close proximity to PI-positive endothelial cells (white arrow). Bar indicates 20 mm.
Ex Vivo Labeling of Atherosclerotic Plaques
To test the uptake of CNA35/OG488 in atherosclerotic plaques, we applied CNA35/OG488 to mounted carotid arteries of ApoE 2/2 mice. Ex vivo administered CNA35/ OG488 labeled all atherosclerotic plaques in the carotid arteries under investigation. Atherosclerotic plaques were typically located in the thickened tunica intima of the bifurcation and exhibited large uptake of CNA35/OG488. Figure 6A is an example of an optical section of an atherosclerotic plaque in the tunica intima. Collagen in the plaques had a matrix-like structure with an inhomogeneous intensity. Many disorderly arranged cells (red arrow) were present between the collagen network. Furthermore, large amounts of strongly labeled collagen were found in the shoulder of plaques, which is marked by a red dotted line in Figure 6B (three-dimensional reconstruction of the shoulder area of an atherosclerotic plaque stained with CNA35/OG488). Interestingly, CNA35/OG488 labeling was also strongly increased in the tunica intima adjacent to the plaque, up to a distance of 150 mm from the edge of the atherosclerotic plaque (lower right part of the three-dimensional reconstruction in Figure 6B ). In healthy arteries, labeling in the tunica intima was almost absent (see Figure 2F ).
In Vivo Labeling of Healthy Arteries and Atherosclerotic Plaques
Concentration of In Vivo Administered CNA35/OG488
All tested doses obtained similar results in healthy and atherosclerotic arteries (and organs), but with differences in signal intensity. Compared with both applied lower doses (single bolus of 200 mL at 19 or 38 mM each, data not shown), infusion of two boluses of 200 mL at 38 mM CNA35/OG488 resulted in the strongest signal intensity.
Healthy Elastic Arteries
In vivo administration of CNA35/OG488 did not result in collagen labeling in the tunica adventitia and tunica media in any section of the carotid artery of wild-type mice. In the tunica intima, only very little CNA35/OG488 (green) uptake was detectable ( Figure 7A ). The blue signal is caused by autofluorescence from the elastic layers. This minimal uptake was located between the endothelial cells (red) and the IEL (inner thin blue layer), as indicated by a white arrow in Figure 7B , a transversal view of a threedimensional reconstruction of the same artery after subsequent labeling of the endothelial cells with anti-CD31/PE.
Atherosclerotic Plaques
As in wild-type mice, intravenous administration of CNA35/OG488 did not result in collagen labeling in the tunica adventitia and media in the elastic arteries of ApoE 2/2 mice (not shown). This is indicative of the inability of the luminally present probe to enter this medial layer in vivo in both healthy and atherosclerotic arteries. However, in ApoE 2/2 mice, in vivo administration of CNA35/OG488 resulted in widespread labeling of collagen in the atherosclerotic plaques and the tunica intima immediately adjacent to the plaques ( Figure 7C) , which is clearly different from the limited CNA35/OG488 labeling in healthy arteries (see Figure 7A ). The detected collagen in the plaque region again had a network-like shape, and the plaque shoulder (red dotted line) exhibited intense CNA35/OG488 labeling (see Figure 7C) , as was the case in the ex vivo labeled atherosclerotic plaques. In vivo administered CNA35/OG488 stained all atherosclerotic plaques in the examined carotid arteries.
Organs with Different Endothelial Phenotypes
To determine the role of the endothelium as a limiting barrier for CNA35/OG488 uptake, several organs of wildtype and ApoE 2/2 mice with different endothelial phenotypes were checked for the presence of CNA35/ OG488 after in vivo (intravenous) administration. Organs with fenestrated or discontinuous endothelium, such as the spleen, liver, and kidneys, contained large amounts of CNA35/OG488, mostly localized in the vascular network. Figure 7D displays a nephron that exhibits strong labeling in the glomeruli (I), Bowman's capsules (red arrow), and proximal tubuli (II). This probably results from filtration of CNA35/OG488 through the relative permeable endothelial layer. In contrast, in organs with continuous endothelium, such as the heart and lungs, no CNA35/ OG488 uptake in the vessel wall was observed. Figure 7E displays (healthy) heart tissue in which CNA35/OG488 ). Only a little uptake of CNA35/OG488 (green spots) is detectable. B, Transversal view of a three-dimensional reconstruction of the same artery after ex vivo labeling with anti-CD31/PE (endothelial cells, red). The three elastic layers are distinguishable. The weak CNA35/OG488 signal (white arrow) is noticeable between the IEL (inner blue layer) and endothelial cells (red). C, Optical section of an atherosclerotic plaque in a carotid artery of an ApoE 2/2 mouse. Shoulder of plaque (indicated by red dotted line) is visible in detail and exhibits a strong CNA35/OG488 collagen signal. In the plaque area, a collagen network is visible in detail. D, Optical section of part of a kidney of a C57BL6/J mouse. The glomerulus (I), Bowman's capsule (red arrow), and proximal tubulus (II) are strongly labeled with CNA35/OG488. Other parts of tubuli (III) exhibit no CNA35/OG488 labeling (blue, autofluorescence). E, Optical section of a healthy heart of a C57BL6/J mouse after in vivo infusion of CNA35/OG488. After dissection, myocytes (green arrow), nuclei of myocytes (red arrow), and nuclei of the endothelial cells in the vasculature (yellow arrow) were stained with SYTO 41 (blue, nuclei and cytoplasm). labeling was absent in the vasculature (yellow arrow) and between myocytes (green arrow). CNA35/OG488 was only sporadically detected in full blood smears 45 minutes after in vivo administration.
Discussion
In this study, we visualized collagen in the viable large arteries of control (C57BL6/J) and atherosclerotic (ApoE 2/2 ) mice using the fluorescent collagen marker CNA35/OG488. TPLSM was applied ex vivo to visualize the distribution of this marker in mounted elastic (carotid) and muscular (uterine) arteries. The route of CNA35/OG488 administration, either ex vivo (intraluminal and extraluminal) or in vivo (intraluminal), strongly influences labeling patterns. After ex vivo administration, the muscular arteries (uterine) of C57BL6/J mice exhibited labeling in all layers, whereas in elastic (carotid) arteries, the tunica media remained unlabeled. Interestingly, in 22-week-old ApoE 2/2 mice fed a Western diet, all atherosclerotic lesions and immediately adjacent regions in the carotid artery contained large amounts of CNA35/OG488-labeled collagen. In vivo infusion of CNA35/OG488 in control mice resulted in almost complete absence of labeling in the carotid artery, whereas in the ApoE 2/2 mice exclusively, the atherosclerotic lesions contained large amounts of CNA35/OG488-labeled collagen. These observations establish CNA35/OG488 as a potential molecular imaging agent for atherosclerotic lesions.
We have confirmed the presence of type I, III, and IV collagen in the elastic arteries of mice. Both type I and III collagen (fibrillar collagens 2, 5, 27 ) were found to be present in the tunicae adventitia and media, whereas type IV collagen (basement membrane component 2, 25 ) was present in the tunicae media and intima. Both histologic sections and fresh transversal rings displayed uptake of CNA35/ OG488 at collagen-containing sites in the arterial wall. The elastic laminae were not labeled with CNA35/OG488 and were clearly detectable by their autofluorescence signal. This further demonstrates the low affinity of CNA35 for elastin, the other major component of the extracellular matrix in arteries, 23 confirming the earlier findings of Krahn and colleagues in solid-phase binding assays. 18 These labeling characteristics, together with the ease of application of CNA35 in both viable and nonviable arterial sections and the possibility of conjugating CNA35 with other (non)fluorescent contrast agents, might favor CNA35 as a routine label for collagen in arteries.
Ex vivo (intra-and extraluminal) administration of CNA35/OG488 to both mounted elastic and muscular arteries strongly labeled collagen in the tunica adventitia.
Compared with a previous study using SHG, 10 visualization of collagen in the tunica adventitia based on CNA35/ OG488 labeling provides much better contrast.
Only weak spots of CNA35/OG488 were observed in the tunica intima of elastic arteries, which were mostly located behind PI-positive, nonviable cells. Therefore, these spots in the tunica intima are probably an artifact of mounting procedure. In contrast, in muscular arteries, a hazy CNA35/OG488 layer in the tunica intima was accompanied by few intense spots. The combination of the presence of subendothelial collagen labeling in Figure  1A (histology, type IV collagen antibody), Figure 1C (fresh arterial ring, CNA35/OG488 localized immediately on the luminal side of the IEL), Figure 4A (mounted artery after pinching with a forceps shows enhanced uptake of CNA35/ OG488 in exactly that layer), and Figure 7B (after in vivo administration, CNA35/OG488 uptake is clearly visible behind the anti-CD31 stained endothelial cells) demonstrates that the diffuse layer in Figure 2 , E and F, is subendothelial collagen. It is known that endothelial cells are not the same throughout the cardiovascular system. 28 This may result in variations in permeability, 28 which may account for the differences in intimal CNA35/OG488 uptake between elastic and muscular arteries. This hypothesis of endothelial cells as a barrier for probe uptake is supported by two findings: (1) the subendothelial collagen layer is strongly labeled after mechanical damage of a carotid artery, which results in a loss of endothelial cell integrity while leaving the IEL visually intact (see Figure  4B ), and (2) after in vivo administration of CNA35/ OG488, organs with either discontinuous endothelial vascular coverage (liver, spleen) or fenestrated endothelium (kidney) exhibit labeling of collagen in subendothelial layers of blood vessels; in organs with continuous endothelium (heart and lungs 23, 29 ), no such labeling was observed. One should realize that the endothelial barrier is important especially after intravenous administration in vivo. In contrast to ex vivo labeling, the probe is present at relevant concentrations only during a narrow time window. It circulates in the blood only for a limited time and with a fast decaying concentration, as demonstrated by the fact that already 30 minutes after probe administration, CNA35/OG488 is no longer detectable in full blood.
The tunica media of muscular arteries contained CNA35/OG488 near the IEL and EEL and between vSMCs. In contrast, the tunica media in elastic arteries was not labeled by ex vivo administered CNA35/OG488, independent of the applied labeling concentration. It can be excluded that CNA35/OG488 is not sensitive for collagen in the tunica media. Indeed, the tunica media of fresh transversal rings and fixed histologic sections of elastic arteries contained CNA35/OG488-labeled collagen. More likely, the absence of CNA35/OG488 uptake in the tunica media is caused by barriers the probe meets on diffusion through the artery. As indicated above, one of the probable barriers is the endothelial cell layer. However, although subendothelial intimal labeling by CNA35/ OG488 was increased adjacent to areas with PI-positive endothelial cells (ie, cells with a compromised membrane), the tunica media showed no increased labeling in those regions. Furthermore, vascular damage induced an increased uptake of CNA35/OG488 in the tunica intima but not in the tunicae media or adventitia. These results indicate that although (viable) endothelial cells are determinants for ex vivo CNA35/OG488 labeling in the tunica intima, they are not the only barrier for uptake in the tunica media. More probably, the geometry and high density of elastin in elastic arteries compared with muscular arteries 10 explain the differences in medial labeling between these vessels. Elastin is a known barrier for movement of water and solutes through the vessel wall. 30 Compared with muscular arteries, the geometry of the IEL and EEL in the thick elastic arteries is much more compact and the number and size of fenestrae are smaller (see Figure 2 ). 10 Indeed, in muscular arteries, CNA35/ OG488 labeling in the tunica media seems to be in close proximity to fenestrae in the IEL. Furthermore, after mechanical damage of the carotid artery, the elastin layer seems to be unaffected with unaltered medial collagen staining (see Figure 4B) .
In contrast to healthy arteries, a large amount of CNA35/ OG488 uptake was observed in all atherosclerotic lesions in ex vivo labeled mounted arteries of 20-to 22-week-old ApoE 2/2 mice (fed a Western diet). The borders (shoulders) of atherosclerotic plaques contained large amounts of collagen. Inside the plaque, a matrix-like network of collagen was detected. No CNA35/OG488 uptake was detected inside the lipid core. Although only a little collagen is expected in the lipid core of advanced plaques, 31 it cannot be excluded that lipids limit the penetration depth of CNA35/OG488. Furthermore, lipids also restrict the penetration depth of TPLSM. The IEL, which appeared to limit CNA35/OG488 uptake in the tunica media of ex vivo labeled control elastic arteries, cannot be the limiting factor of penetration depth in plaques since plaques are mainly located in the tunica intima. Remarkably, an increase in CNA35/OG488 labeling in the tunica intima was detected in the arterial wall adjacent to a plaque. This suggests an increase in collagen content in these areas. It is indeed known that collagen content increases in parallel with progression of atherosclerosis. 3, 5, 32 However, increased permeability of endothelial cells in plaque regions 31, 33 may also cause stronger CNA35/OG488 labeling of the generally present collagen in the tunica intima in the area adjacent to atherosclerotic plaques.
In vivo administration (systemic infusion) of CNA35/ OG488 in control mice resulted in barely any uptake in the healthy elastic (carotid) arteries. The tunica intima exhibited only very little uptake of CNA35/OG488, whereas the tunica media was unlabeled. Also, collagen in the tunica adventitia was not labeled, which is a consequence of both the absence of extraluminal CNA35/OG488 labeling after in vivo administration and the inability of CNA35/OG488 to reach the tunica adventitia from the luminal side. In contrast, in vivo administration in atherosclerotic mice resulted in a massive CNA35/OG488 labeling of all atherosclerotic plaques. This result was very much similar to findings after ex vivo labeling, suggesting the absence of diffusion barriers. In both situations, the matrix-like network of the collagen in the plaques was visualized and an increase in CNA35/OG488 uptake was detected in the arterial wall adjacent to the plaque.
The minimal uptake of CNA35/OG488 in healthy elastic arteries and the high uptake in atherosclerotic arteries after in vivo administration allow differentiation between healthy and atherosclerotic sites and demonstrate the feasibility of CNA35 as a molecular imaging agent for atherosclerosis (although the exact pharmacokinetics of CNA35/OG488 are still unknown). Given that collagen content and endothelial permeability are both determinants for plaque stability, the total CNA35 uptake may provide information about both indicators of plaque stability. 4, 5, 31, 33, 34 However, quantification of CNA35 uptake in fluorescence imaging is tedious. Conjugation of CNA35 with, for example, single-photon emission computed tomographic probes may allow such quantification. Also, conjugation of CNA35 with other (multimodal) contrast agents will enable use of imaging modalities such as magnetic resonance imaging and positron emission tomography, allowing both invasive and noninvasive functional and structural imaging. This further establishes the potential of CNA35 as a molecular imaging agent of both early and late stages of atherosclerosis. However, CNA35/OG488 does not allow for detection of all vulnerable plaques, such as eroded plaques or plaques with mild or moderate calcification (plaque morphologies associated with acute coronary thrombi). 35 Since the vulnerability for plaque rupture is potentially a plural process, unequivocally, detection of all vulnerable plaques would require multitargeted probes. The in vivo labeling characteristics of CNA35/OG488 in kidneys, heart, and liver underline its potential as a molecular agent in other tissues as well.
Therefore, CNA35/OG488 may also be a valuable tool for studying diseases such as heart failure, wound healing, or diabetes, for which alterations of collagen content or the intactness of endothelium may be of importance.
